Affymetrix Investing in Instrumentation, Genotyping Arrays as Genetic Analysis Sales Drive Q2 Revenues | GenomeWeb

NEW YORK (GenomeWeb) – The array market seems poised for a number of new product launches in coming years as Affymetrix recently confirmed that it is developing a next-generation instrument platform.

CFO Gavin Wood said on the company's second quarter earnings call last week that a slight spike in R&D expenses during the quarter was "largely driven by the initiation of spend on a new platform."

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: new single-cell RNA sequencing technique to study proliferating cells, and more.

South African researchers uncover bone cancer in an ancient hominin ancestor.

English bulldogs suffer from low genetic diversity and might have to be outbred to improve their health, according to a new study.

Theresa May tries to reassure researchers about the UK's commitment to science, New Scientist reports.